Global Myasthenia Gravis Treatment Market: Forecast and Trends
Report Scope:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.
Report Includes:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.
Report Includes:
- 54 data tables and 47 additional tables
- An overview and analysis of the global market for myasthenia gravis (MG) treatments
- Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
- In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
- Analysis of the market growth opportunities through Porter’s Five Forces and PESTLE analyses, taking into consideration the prevailing micro%li%and macro environmental factors
- An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
- Discussion of the factors driving the market, industry trends and new developments
- Analysis of relevant patents
- Identification of the leaders in the field of MG
- Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Outlook
Report Highlights
CHAPTER 3 MARKET OVERVIEW
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints
CHAPTER 5 MARKET BREAKDOWN BY REGION
Market Overview
North America
Europe
Asia-Pacific
CHAPTER 6 MARKET BREAKDOWN BY TYPE
Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis
CHAPTER 7 MARKET BREAKDOWN BY TREATMENT MODALITY
Introduction
Medications
Surgery
Intravenous Therapy
CHAPTER 8 MARKET BREAKDOWN BY TYPE OF PRODUCT
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
CHAPTER 9 ESG DEVELOPMENT
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
CHAPTER 10 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Introduction
CHAPTER 11 COMPETITIVE INTELLIGENCE
Overview
Industry Scenario
Company Shares
CHAPTER 12 PATENT ANALYSIS
Patent Analysis by Manufacturer
CHAPTER 13 PIPELINE ANALYSIS
Clinical Trials
CHAPTER 14 M&A AND VENTURE FUNDING OUTLOOK
Introduction
CHAPTER 15 COMPANY PROFILES
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
CHAPTER 16 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Outlook
Report Highlights
CHAPTER 3 MARKET OVERVIEW
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications
CHAPTER 4 MARKET DYNAMICS
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints
CHAPTER 5 MARKET BREAKDOWN BY REGION
Market Overview
North America
Europe
Asia-Pacific
CHAPTER 6 MARKET BREAKDOWN BY TYPE
Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis
CHAPTER 7 MARKET BREAKDOWN BY TREATMENT MODALITY
Introduction
Medications
Surgery
Intravenous Therapy
CHAPTER 8 MARKET BREAKDOWN BY TYPE OF PRODUCT
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
CHAPTER 9 ESG DEVELOPMENT
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
CHAPTER 10 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Introduction
CHAPTER 11 COMPETITIVE INTELLIGENCE
Overview
Industry Scenario
Company Shares
CHAPTER 12 PATENT ANALYSIS
Patent Analysis by Manufacturer
CHAPTER 13 PIPELINE ANALYSIS
Clinical Trials
CHAPTER 14 M&A AND VENTURE FUNDING OUTLOOK
Introduction
CHAPTER 15 COMPANY PROFILES
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
CHAPTER 16 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide
Table 3 : Global Serological Testing for Myasthenia Gravis, by Type
Table 4 : Targeted Drug Therapies for the Treatment of Myasthenia Gravis
Table 5 : Diagnostic Challenges in the Treatment of Myasthenia Gravis
Table 6 : Risks of Emerging Therapies for Myasthenia Gravis, by Type
Table 7 : Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 8 : North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 9 : European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 10 : Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 11 : Global Prevalence of Myasthenia Gravis, by Type
Table 12 : Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028
Table 13 : Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028
Table 14 : Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028
Table 15 : Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 16 : Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028
Table 17 : Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 19 : Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 20 : Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 21 : Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 22 : Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 23 : Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 24 : ESG Framework for the Global Pharmaceutical Industry
Table 25 : Social Framework of the Global Pharmaceutical Industry
Table 26 : Top Pharma Companies: ESG Ratings
Table 27 : AstraZeneca’s Contribution to Sustainable Development Goals
Table 28 : AstraZeneca’s Material Focus Areas
Table 29 : New Technologies for Myasthenia Gravis Treatments
Table 30 : New Pharmaceuticals for the Treatment of Myasthenia Gravis
Table 31 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Table 32 : Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022
Table 33 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Table 34 : Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022
Table 35 : Patents on Myasthenia Gravis Treatments, 2018-Present
Table 36 : Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present
Table 37 : Patents on Eculizumab, 2018-Present
Table 38 : Selected Manufacturer Patents on Eculizumab, 2018-Present
Table 39 : Patents on Efgartigimod alfa, 2018-Present
Table 40 : Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present
Table 41 : Patents on Rituximab, 2018-Present
Table 42 : Selected Manufacturer Patents on Rituximab, 2018-Present
Table 43 : Patents on Pyridostigmine, 2018-Present
Table 44 : Selected Manufacturer Patents on Pyridostigmine, 2018-Present
Table 45 : Patents on Privigen, 2018-Present
Table 46 : Selected Manufacturer Patents on Privigen, 2018-Present
Table 47 : Clinical Trials on Myasthenia Gravis, as of 2023
Table 48 : Mergers and Acquisitions, 2019-2021
Table 49 : AbbVie: Product Information
Table 50 : AbbVie: Financial Overview, 2020-2022
Table 51 : AbbVie: Key Developments, 2021-2023
Table 52 : Amgen: Revenue, 2020-2022
Table 53 : Amgen: Key Developments, 2021 and 2022
Table 54 : Astellas Pharma: Revenue, 2020-2022
Table 55 : Astellas Pharma: Key Developments, 2018-2022
Table 56 : AstraZeneca: Product Information
Table 57 : AstraZeneca: Revenue, 2020-2022
Table 58 : AstraZeneca: Key Developments, 2022 and 2023
Table 59 : Bausch Health: Product Information
Table 60 : Bausch Health: Revenue, 2020-2022
Table 61 : Bayer AG: Product Information
Table 62 : Bayer AG: Financial Overview, 2020-2022
Table 63 : Bayer AG: Key Developments, 2022 and 2023
Table 64 : Biogen: Financial Overview, 2020-2022
Table 65 : Biogen: Key Developments, 2018-2023
Table 66 : Bristol-Myers Squibb: Product Information
Table 67 : Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68 : Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69 : CSL: Product Information
Table 70 : CSL: Revenue, 2020-2022
Table 71 : CSL: Recent Developments, 2022
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Financial Overview, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Roche: Product Information
Table 76 : Roche: Revenue, 2020-2022
Table 77 : Roche: Key Developments, 2021-2023
Table 78 : Gilead Sciences: Financial Overview, 2020-2022
Table 79 : Gilead Sciences: Key Developments, 2022
Table 80 : GlaxoSmithKline plc: Product Segments
Table 81 : GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82 : GlaxoSmithKline plc: Recent Developments, 2022
Table 83 : Merck & Co. Inc.: Business Segments
Table 84 : Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85 : Merck & Co. Inc.: Key Developments, 2022
Table 86 : Novartis: Product Information
Table 87 : Novartis: Financial Overview, 2020-2022
Table 88 : Novartis: Key Developments, 2023
Table 89 : Pfizer Inc: Product Segments
Table 90 : Pfizer Inc: Financial Overview, 2020-2022
Table 91 : Pfizer Inc: Top Brands, 2022
Table 92 : Pfizer Inc: Key Developments, 2019-2023
Table 93 : Sanofi: Business Segments
Table 94 : Sanofi: Annual Revenue, 2020-2022
Table 95 : Sanofi: Key Developments, 2021-2023
Table 96 : Servier: Annual Revenue, 2020-2022
Table 97 : Servier: Key Developments, 2022 and 2023
Table 98 : Teva: Financial Overview, 2020-2022
Table 99 : Teva: Key Developments, 2021-2023
Table 100 : Acronyms
Summary Table : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : Factors Leading to the Increasing Incidence of Myasthenia Gravis Worldwide
Table 3 : Global Serological Testing for Myasthenia Gravis, by Type
Table 4 : Targeted Drug Therapies for the Treatment of Myasthenia Gravis
Table 5 : Diagnostic Challenges in the Treatment of Myasthenia Gravis
Table 6 : Risks of Emerging Therapies for Myasthenia Gravis, by Type
Table 7 : Global Market for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 8 : North American Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 9 : European Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 10 : Asia-Pacific Market for the Treatment of Myasthenia Gravis, by Country, Through 2028
Table 11 : Global Prevalence of Myasthenia Gravis, by Type
Table 12 : Global Market for the Treatment of Generalized Myasthenia Gravis, by Region, Through 2028
Table 13 : Global Market for the Treatment of Ocular Myasthenia Gravis, by Region, Through 2028
Table 14 : Global Market for the Treatment of Transient Neonatal Myasthenia Gravis, by Region, Through 2028
Table 15 : Global Market for Medications for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 16 : Global Market for Surgical Treatment of Myasthenia Gravis, by Region, Through 2028
Table 17 : Global Market for Intravenous Therapy for the Treatment of Myasthenia Gravis, by Region, Through 2028
Table 18 : Global Market for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 19 : Global Market for Monoclonal Antibodies for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 20 : Global Market for Cholinesterase Inhibitors for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 21 : Global Market for Intravenous Immunoglobulins for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 22 : Global Market for Immunosuppressants for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 23 : Global Market for Corticosteroids for the Treatment of Myasthenia Gravis, by Type of Product, Through 2028
Table 24 : ESG Framework for the Global Pharmaceutical Industry
Table 25 : Social Framework of the Global Pharmaceutical Industry
Table 26 : Top Pharma Companies: ESG Ratings
Table 27 : AstraZeneca’s Contribution to Sustainable Development Goals
Table 28 : AstraZeneca’s Material Focus Areas
Table 29 : New Technologies for Myasthenia Gravis Treatments
Table 30 : New Pharmaceuticals for the Treatment of Myasthenia Gravis
Table 31 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Table 32 : Global Product Shares of Myasthenia Gravis Treatments, by Brand, 2022
Table 33 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Table 34 : Key Financials of Pharma Companies Offering Myasthenia Gravis Treatment Products, 2022
Table 35 : Patents on Myasthenia Gravis Treatments, 2018-Present
Table 36 : Selected Manufacturer Patents on Myasthenia Gravis Drugs, 2018-Present
Table 37 : Patents on Eculizumab, 2018-Present
Table 38 : Selected Manufacturer Patents on Eculizumab, 2018-Present
Table 39 : Patents on Efgartigimod alfa, 2018-Present
Table 40 : Selected Manufacturer Patents on Efgartigimod alfa, 2018-Present
Table 41 : Patents on Rituximab, 2018-Present
Table 42 : Selected Manufacturer Patents on Rituximab, 2018-Present
Table 43 : Patents on Pyridostigmine, 2018-Present
Table 44 : Selected Manufacturer Patents on Pyridostigmine, 2018-Present
Table 45 : Patents on Privigen, 2018-Present
Table 46 : Selected Manufacturer Patents on Privigen, 2018-Present
Table 47 : Clinical Trials on Myasthenia Gravis, as of 2023
Table 48 : Mergers and Acquisitions, 2019-2021
Table 49 : AbbVie: Product Information
Table 50 : AbbVie: Financial Overview, 2020-2022
Table 51 : AbbVie: Key Developments, 2021-2023
Table 52 : Amgen: Revenue, 2020-2022
Table 53 : Amgen: Key Developments, 2021 and 2022
Table 54 : Astellas Pharma: Revenue, 2020-2022
Table 55 : Astellas Pharma: Key Developments, 2018-2022
Table 56 : AstraZeneca: Product Information
Table 57 : AstraZeneca: Revenue, 2020-2022
Table 58 : AstraZeneca: Key Developments, 2022 and 2023
Table 59 : Bausch Health: Product Information
Table 60 : Bausch Health: Revenue, 2020-2022
Table 61 : Bayer AG: Product Information
Table 62 : Bayer AG: Financial Overview, 2020-2022
Table 63 : Bayer AG: Key Developments, 2022 and 2023
Table 64 : Biogen: Financial Overview, 2020-2022
Table 65 : Biogen: Key Developments, 2018-2023
Table 66 : Bristol-Myers Squibb: Product Information
Table 67 : Bristol-Myers Squibb: Financial Overview, 2020-2022
Table 68 : Bristol-Myers Squibb: Key Developments, 2021-2023
Table 69 : CSL: Product Information
Table 70 : CSL: Revenue, 2020-2022
Table 71 : CSL: Recent Developments, 2022
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Financial Overview, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Roche: Product Information
Table 76 : Roche: Revenue, 2020-2022
Table 77 : Roche: Key Developments, 2021-2023
Table 78 : Gilead Sciences: Financial Overview, 2020-2022
Table 79 : Gilead Sciences: Key Developments, 2022
Table 80 : GlaxoSmithKline plc: Product Segments
Table 81 : GlaxoSmithKline plc: Financial Overview, 2020-2022
Table 82 : GlaxoSmithKline plc: Recent Developments, 2022
Table 83 : Merck & Co. Inc.: Business Segments
Table 84 : Merck & Co. Inc.: Financial Overview, 2020-2022
Table 85 : Merck & Co. Inc.: Key Developments, 2022
Table 86 : Novartis: Product Information
Table 87 : Novartis: Financial Overview, 2020-2022
Table 88 : Novartis: Key Developments, 2023
Table 89 : Pfizer Inc: Product Segments
Table 90 : Pfizer Inc: Financial Overview, 2020-2022
Table 91 : Pfizer Inc: Top Brands, 2022
Table 92 : Pfizer Inc: Key Developments, 2019-2023
Table 93 : Sanofi: Business Segments
Table 94 : Sanofi: Annual Revenue, 2020-2022
Table 95 : Sanofi: Key Developments, 2021-2023
Table 96 : Servier: Annual Revenue, 2020-2022
Table 97 : Servier: Key Developments, 2022 and 2023
Table 98 : Teva: Financial Overview, 2020-2022
Table 99 : Teva: Key Developments, 2021-2023
Table 100 : Acronyms
LIST OF FIGURES
Summary Figure A : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028
Summary Figure B : Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022
Figure 1 : Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022
Figure 2 : Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022
Figure 3 : North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 4 : European Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 5 : Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 6 : Global Distribution of Types of Myasthenia Gravis, 2022
Figure 7 : Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022
Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022
Figure 9 : Global Electricity Production from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO2 Emissions, 2017-2021
Figure 12 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Figure 13 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Figure 14 : AbbVie: Revenue Shares, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Country/Region, 2022
Figure 17 : Gilead Sciences: Revenue, by Type of Product, 2022
Figure 18 : GlaxoSmithKline plc: Annual Revenue, by Segment, 2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022
Figure 20 : Novartis Innovative Medicines: Market Share, by Country/Region, 2022
Figure 21 : Novartis Sandoz: Market Share, by Country/Region 2022
Figure 22 : Sanofi: Revenue, by Region, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022
Summary Figure A : Global Market for the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2020-2028
Summary Figure B : Global Market Shares of the Treatment of Myasthenia Gravis, by Type of Myasthenia Gravis, 2022
Figure 1 : Global Factors Leading to the Prevalence of Myasthenia Gravis, by Region, 2022
Figure 2 : Global Market Shares of Myasthenia Gravis Treatments, by Region, 2022
Figure 3 : North American Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 4 : European Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 5 : Asia-Pacific Market Shares of Myasthenia Gravis Treatments, by Country, 2022
Figure 6 : Global Distribution of Types of Myasthenia Gravis, 2022
Figure 7 : Global Market Shares of Myasthenia Gravis Treatments, by Treatment Modality, 2022
Figure 8 : Global Market Shares of Myasthenia Gravis Treatments, by Type of Product, Through 2022
Figure 9 : Global Electricity Production from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO2 Emissions, 2017-2021
Figure 12 : Global Company Market Shares of Myasthenia Gravis Treatments, 2022
Figure 13 : Global Sales of Myasthenia Gravis Treatments, by Brand, 2022
Figure 14 : AbbVie: Revenue Shares, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country/Region, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Country/Region, 2022
Figure 17 : Gilead Sciences: Revenue, by Type of Product, 2022
Figure 18 : GlaxoSmithKline plc: Annual Revenue, by Segment, 2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, Pharmaceutical Segment, 2022
Figure 20 : Novartis Innovative Medicines: Market Share, by Country/Region, 2022
Figure 21 : Novartis Sandoz: Market Share, by Country/Region 2022
Figure 22 : Sanofi: Revenue, by Region, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022
